| Literature DB >> 23533546 |
Yu-wen Lv1, Jing Wang, Ling Sun, Jian-min Zhang, Lei Cao, Yue-yue Ding, Ye Chen, Ji-juan Dou, Jie Huang, Yi-fei Tang, Wen-tao Wu, Wei-rong Cui, Hai-tao Lv.
Abstract
Kawasaki disease (KD) is a complex disease, leading to the damage of multisystems. The pathogen that triggers this sophisticated disease is still unknown since it was first reported in 1967. To increase our knowledge on the effects of genes in KD, we extracted statistically significant genes so far associated with this mysterious illness from candidate gene studies and genome-wide association studies. These genes contributed to susceptibility to KD, coronary artery lesions, resistance to initial IVIG treatment, incomplete KD, and so on. Gene ontology category and pathways were analyzed for relationships among these statistically significant genes. These genes were represented in a variety of functional categories, including immune response, inflammatory response, and cellular calcium ion homeostasis. They were mainly enriched in the pathway of immune response. We further highlighted the compelling immune pathway of NF-AT signal and leukocyte interactions combined with another transcription factor NF- κ B in the pathogenesis of KD. STRING analysis, a network analysis focusing on protein interactions, validated close contact between these genes and implied the importance of this pathway. This data will contribute to understanding pathogenesis of KD.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23533546 PMCID: PMC3606754 DOI: 10.1155/2013/989307
Source DB: PubMed Journal: Comput Math Methods Med ISSN: 1748-670X Impact factor: 2.238
Candidate gene studies identified genes associated with KD.
| Symbol | Region | Phenotype | Country | Reference |
|---|---|---|---|---|
| CD40 | 20q12-q13.2 | KD | Taiwan | [ |
| CAL | Taiwan | [ | ||
| CD209 | 19p13 | KD | Taiwan | [ |
| RETN | 19p13.2 | Incomplete KD | China | [ |
| KD | United States | [ | ||
| CAL | Japan | [ | ||
| FCGR3B | 1q23 | IVIG nonresponse | United States | [ |
| NOD1 | 7p15-p14 | KD | Japan | [ |
| NLRP1 | 17p13.2 | KD | Japan | [ |
| ITPKC | 19q13.1 | KD | Taiwan; Japan; China | [ |
| CAL | Japan | [ | ||
| IVIG nonresponse | Japan | [ | ||
| TGFBR2 | 3p22 | KD | European descent; Korea | [ |
| CAL | European descent; Korea | [ | ||
| IVIG nonresponse | European descent | [ | ||
| aortic root dilatation, | European descent | [ | ||
| ABO | 9q34.2 | CAL | Japan | [ |
| PELI1 | 2p13.3 | CAL | Korea | [ |
| SMAD3 | 15q22.33 | KD | European descent; Taiwan | [ |
| CAL | European descent | [ | ||
| IVIG nonresponse | European descent | [ | ||
| aortic root dilatation | European descent | [ | ||
| TGFB2 | 1q41 | KD | European descent; Taiwan | [ |
| CAL | European descent | [ | ||
| IVIG nonresponse | European descent | [ | ||
| aortic root dilatation, | European descent | [ | ||
| CASP3 | 4q34 | CAL | Taiwan; Japan | [ |
| IVIG nonresponse | Japan | [ | ||
| ANGPT1 | 8q23.1 | KD | Netherlands | [ |
| VEGFA | 6p12 | KD | Netherlands; Taiwan; The Netherlands. | [ |
| CAL | Japan | [ | ||
| MICB | 6p21.3 | KD | Taiwan | [ |
| CAL | Taiwan | [ | ||
| MICA | 6p21.33 | KD | Taiwan | [ |
| CAL | Taiwan | [ | ||
| BAG6 | 6p21.3 | KD | Taiwan | [ |
| CAA | Taiwan | [ | ||
| MSH5 | 6p21.3 | KD | Taiwan | [ |
| VWA7 | 6p21.33 | KD | Taiwan | [ |
| FCGR2B | 1q23 | IVIG nonresponse | Pacific Northwest | [ |
| IL10 | 1q31-q32 | KD | Taiwan | [ |
| CAL | China; Korea; Taiwan | [ | ||
| CCL5 | 17q11.2-q12 | CAL | India | [ |
| TNFRSF1A | 12p13.2 | KD | China | [ |
| CTLA4 | 2q33 | CAL (particularly in female patients) | Taiwan | [ |
| MMP3 | 11q22.3 | CAL | Korea; US-UK, tested in Japan | [ |
| MMP12 | 11q22.3 | CAL | US-UK, tested in Japan | [ |
| FGB | 4q28 | CAL | China | [ |
| CCL3L1 | 17q21.1 | KD | USA; Japan | [ |
| IVIG nonresponse | Japan | [ | ||
| CCR5 | 3p21.31 | KD | USA; The Netherlands (Dutch Caucasian); Korea | [ |
| CAL | Japan | [ | ||
| IVIG nonresponse | Japan | [ | ||
| PRRC2A | 6p21.3 | KD | Taiwan | [ |
| CAL | Taiwan | [ | ||
| ABHD16A | 6p21.3 | KD | Taiwan | [ |
| CAL | Taiwan | [ | ||
| ITPR3 | 6p21 | CAL | Taiwan | [ |
| COL11A2 | 6p21.3 | KD | Taiwan | [ |
| CAL | Taiwan | [ | ||
| MBL2 | 10q11.2 | KD | China; Japan | [ |
| CAL | The Netherlands; The Netherlands | [ | ||
| Arterial stiffness | China | [ | ||
| MMP11 | 22q11.23 | KD | Korea | [ |
| MIF | 22q11.23 | CAL | Italy | [ |
| IL1B | 2q14 | IVIG nonresponse | Taiwan | [ |
| BTNL2 | 6p21.3 | KD | Taiwan | [ |
| CAL | Taiwan | [ | ||
| TPH2 | 12q21.1 | CAL | Korea | [ |
| PDCD1 | 2q37.3 | KD | Korean | [ |
| IL18 | 11q22.2-q22.3 | KD | Taiwan | [ |
| HLA-E | 6p21.3 | KD | Taiwan | [ |
| CAL | Taiwan | [ | ||
| TIMP4 | 3p25 | CAL | Korea | [ |
| HLA-G | 6p21.3 | KD | Korea | [ |
| CRP | 1q21-q23 | KD | China | [ |
| Carotid stiffness and carotid intima-media thickness | China | [ | ||
| TNF | 6p21.3 | KD | China | [ |
| CAL | white | [ | ||
| Intima-media thickness | China | [ | ||
| IVIG nonresponse | China | [ | ||
| MMP13 | 11q22.3 | CAL | Japan | [ |
| HLA-B | 6p21.3 | KD | Korea | [ |
| HLA-C | 6p21.3 | KD | Korea | [ |
| CCR3 | 3p21.3 | KD | Netherlands (Dutch Caucasian) | [ |
| CCR2 | 3p21.31 | KD | Netherlands (Dutch Caucasian) | [ |
| TIMP2 | 17q25 | CAL | Japan | [ |
| ACE | 17q23.3 | KD | Taiwan; Korea | [ |
| Coronary artery stenosis | Japan | [ | ||
| Myocardial ischemia | Japan | [ | ||
| PLA2G7 | 6p21.2-p12 | IVIG nonresponse | Japan | [ |
| IL1RN | 2q14.2 | KD | Taiwan | [ |
| IL4 | 5q31.1 | KD | USA | [ |
| KDR | 4q11-q12 | CAL | Japan | [ |
| CD40LG | Xq26 | CAL: males affected | Japan | [ |
| AGTR1 | 3q24 | Coronary artery stenosis and myocardial ischemia | Japan | [ |
| CD14 | 5q31.1 | CAL | Japan | [ |
| SLC11A1 | 2q35 | KD | Japan | [ |
| LTA | 6p21.3 | KD | white | [ |
| MTHFR | 1p36.3 | CAL | Japan | [ |
| HP | 16q22.2 | late diagnosis of KD | Taiwan | [ |
KD: kawasakidisease;CAL: coronary artery lesions; CAA: coronary artery aneurysms.
Susceptibility genes for KD identified with association at genome-wide significance.
| Gene | Locus | Methods | Reference |
|---|---|---|---|
| FCGR2A | 1q23 | GWAS | [ |
| BLK | 8p23-p22 | GWAS | [ |
| CASP3 | 4q34 | Genome wide Linkage analysis | [ |
| ITPKC | 19q13.1 | Genome wide Linkage analysis; linkage disequilibrium mapping | [ |
| CD40L | Xq26 | Genome wide Linkage analysis | [ |
| CD40 | 20q12-q13.2 | GWAS | [ |
| HLA-DQB2 | 6p21 | GWAS | [ |
| HLA-DOB | 6p21.3 | GWAS | [ |
| NFKBIL1 | 6p21.3 | GWAS | [ |
| LTA | 6p21.3 | GWAS | [ |
| NAALADL2 | 3q26.31 | GWAS | [ |
| ZFHX3 | 16q22.3 | GWAS | [ |
| DAB1 | 1p32-p31 | GWAS | [ |
| PELI1 | 2p13.3 | GWAS | [ |
| COPB2 | 3q23 | GWAS | [ |
| ERAP1 | 5q15 | GWAS | [ |
| IGHV | 14q32.33 | GWAS | [ |
| ABCC4 | 13q32 | Genome-wide linkage and association mapping | [ |
GWAS: genome-wide association study.
Figure 1Enrichment analysis of the genes by GeneGo MetaCore: (a) GO Processes, (b) Go Pathway Maps, (c) Go Diseases (by Biomarkers). MetaCore version 6.11 build 41105.
Pathways analyzed by GeneGo Meta core.
| Pathway categories | Pathways | Functions | Enrichment genes |
|---|---|---|---|
| Immune response | (1) HSP60 and HSP70/TLR signaling pathway | Pro-inflammatory response and anti-inflammatory response; cellular and humoral immune response; NO production; apoptosis and antiapoptosis; secretion of leukotrienes and prostaglandins; proliferation and differentiation of eosinophils; chemotaxis; proliferation, differentiation, activation of T cell; cell necrosis; smooth muscle construction; vascular permeability; blood coagulation; cytoskeleton remodeling | CD14, HSP70, IL-10, TNF- |
|
| |||
| Cell adhesion | Plasmin signaling | Fibrinolysis; cell viability | TGF- |
|
| |||
| Development | (1) Cross-talk between VEGF and Angiopoietin 1 signaling pathways | Leukocyte-endothelial adhesion; epithelial-to-mesenchymal transition; proteasomal degradation; inhibition of angiogenesis; immune response | VEGF-A, VEGFR-2, Angiopoietin 1, IP3 receptor, TGF- |
|
| |||
| Apoptosis and survival | (1) Role of IAP-proteins in apoptosis | Caspase dependent and independent apoptosis; apoptosis and antiapoptosis | TNF- |
|
| |||
| Transcription | NF-kB signaling pathway | Activate the transcription of target genes | TNF- |
FDR = 0.01.
Figure 2STRING analysis of the relationship between genes. The network nodes represent the proteins encoded by the genes. Seven different colored lines link a number of nodes and represent seven types of evidence used in predicting associations. Among these significant genes, VWA7, PRRC2A, and ABHD16A were not identified. A red line indicates the presence of fusion evidence; a green line represents neighborhood evidence; a blue line represents cooccurrence evidence; a purple line represents experimental evidence; a yellow line represents text mining evidence; a light blue line represents database evidence [100, 101] and a black line represents coexpression evidence.
Figure 3NF-AT signaling and leukocyte interactions have been enriched by GeneGo.